What we do
Oslo Cancer Cluster is working on several projects aiming to accelerate the development of new cancer treatments. The following page contains a brief overview of the projects we are currently working on and our previous projects.
Oslo Cancer Cluster is working on several projects aiming to accelerate the development of new cancer treatments. The following page contains a brief overview of the projects we are currently working on and our previous projects.
The Incubator provides a dynamic, creative and professional growth environment for scientists & start-ups. A dedicated Incubator team offers the tenants of the Incubator business development services covering key development areas, access to an extensive international network of key industry players, as well as facilitate investor contacts.
The DIGI-B-CUBE project aims to foster the development of customized solutions and prototypes for the healthcare sector. In 2022, the project has funded a total of 55 projects, resulting in 2,5 MEUR provided directly to European small and medium-sized companies (SMEs) to boost the development of disruptive tech solutions and health tech innovations. Oslo Cancer Cluster and eight European partners will deliver the results of this EU project in the summer of 2022.
Attracting and developing the life science talents of the future is an essential goal for Oslo Cancer Cluster. By taking the students outside the traditional classroom setting and inviting them to work placements and educational lectures, the students gain a unique insight into the specialist skills needed to become tomorrow’s researchers and entrepreneurs.
CONNECT is a novel public-private partnership driving the implementation of precision cancer medicine. Precision medicine changes healthcare. The implementation of precision medicine requires new types of interactions and partnerships among patients, clinicians, companies, regulators, and payors. CONNECT offers a new national arena for all stakeholders to jointly address key obstacles and pilot novel solutions to transform the current practice.
The aim of the National Program for Personalized Cancer Medicine is to build a national cancer diagnostics platform based on next generation sequencing. This will ensure that every cancer diagnosis triggers molecular testing to identify the right treatment for the individual patient.
The “Norwegian Immuno-Oncology Consortium” kicked off in March 2013. Oslo Cancer Cluster initiated the consortium together with Bristol-Myers Squibb, a leading global player in immuno-oncology. The Consortium aims to further advance education, partnerships and innovation within this highly specialized and disruptive field.
In our role as changemaker, Oslo Cancer Cluster works towards improving the framework conditions for cancer innovations in the Norwegian health industry. This includes contributing input to relevant national policies and addressing specific challenges for the health industry with opinion pieces in the media.
Norway has favourable conditions for attracting clinical trials, such as our unique health data and registries. However, we need to create more cooperative solutions for investing in cancer treatments and foster better collaboration between public and private actors. Therefore, we support establishing a partnership model for clinical studies in Norway.
Oslo Cancer Cluster promotes the Norwegian health industry through a number of activities. We support budding biotechs in our Incubator and across Norway. We help to connect Norwegian health companies with international key players. We assist companies in the cancer field in getting the framework conditions they need to thrive in Norway.
Contact us for more information about our projects or if you have ideas for specific projects we should collaborate on.
Oslo Cancer Cluster is an oncology research and industry cluster dedicated to improving the lives of cancer patients by accelerating the development of new cancer diagnostics and medicines.
We are a national non-profit member organization with about 90 members. Our members are Norwegian and international companies, research and financial institutions, university hospitals and organizations – all working in the cancer field.